(Q45231261)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Paradoxical oncogenesis: are all BRAF inhibitors equal? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

ChEBI release 2020-05-28

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Alexander M Menzies

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Richard F. Kefford

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

Alexander M Menzies

1 reference

11 December 2017

Richard F Kefford

2

1 reference

11 December 2017

publication date

19 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

Pigment Cell & Melanoma Research

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

611-615

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Progression of RAS-mutant leukemia during RAF inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12132

21 January 2018

Identifiers

DOI

10.1111/PCMR.12132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23795808%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference